Palla Pharma Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Palla Pharma Ltd with three other
pharmaceutical manufacturers in Australasia:
Immuron Limited
(2020
sales of 2.52 million Australian Dollars [US$1.92 million]
of which 100%
was HyperImmune Products),
ECS Botanics Holdings Ltd
(919,128.00 Australian Dollars [US$700,017.08 ]
), and
MGC Pharmaceuticals Ltd
(2.09 million Australian Dollars [US$1.59 million]
of which 100%
was Supply of medicinal cannabis products).
Sales Analysis.
Palla Pharma Ltd reported sales of A$22.10 million (US$16.83 million)
for the
year ending
December of 2020.
This
represents
a
sharp
decrease of 59.7%
versus 2019, when the company's sales were A$54.84 million.
Contributing to the drop in overall sales was the 60.6% decline
in Norway, from A$46.64 million to A$18.37 million.
There were also decreases in sales in
Australia (down 33.2% to A$5.37 million)
.